Abstract
As modulators of gene expression, microRNAs (miRNAs) are essential for normal development. Not surprisingly, aberrant expression of miRNAs is associated with many diseases, including cancer. Studies of various breast cancer subtypes have demonstrated that, like gene expression profiles and pathological differences, miRNA profiles can distinguish various tumor subtypes. Over the last few years, roles for miRNAs during many stages of breast cancer progression have been established. This includes potential breast cancer associated polymorphisms in miRNA target sites or miRNAs themselves, miRNAs that can act as tumor suppressors or oncogenes, and miRNAs that can modulate metastatic spread. Recent studies have also suggested key roles for miRNAs in regulating cancer stem cells. Thus, miRNAs have now become important therapeutic targets. This can be achieved by replacing miRNA expression where it has been lost or decreased, or conversely by inhibiting miRNA expression where it has been amplified or overexpressed in cancers. Ultimately, miRNAs should provide both important prognostic biomarkers as well as new targetable molecules for the treatment of breast cancer.
Keywords: Breast cancer, miRNA, novel therapeutics, stem cells
Current Drug Targets
Title: Small Players With Big Roles: MicroRNAs as Targets to Inhibit Breast Cancer Progression
Volume: 11 Issue: 9
Author(s): Stephanie B. Greene, Jason I. Herschkowitz and Jeffrey M. Rosen
Affiliation:
Keywords: Breast cancer, miRNA, novel therapeutics, stem cells
Abstract: As modulators of gene expression, microRNAs (miRNAs) are essential for normal development. Not surprisingly, aberrant expression of miRNAs is associated with many diseases, including cancer. Studies of various breast cancer subtypes have demonstrated that, like gene expression profiles and pathological differences, miRNA profiles can distinguish various tumor subtypes. Over the last few years, roles for miRNAs during many stages of breast cancer progression have been established. This includes potential breast cancer associated polymorphisms in miRNA target sites or miRNAs themselves, miRNAs that can act as tumor suppressors or oncogenes, and miRNAs that can modulate metastatic spread. Recent studies have also suggested key roles for miRNAs in regulating cancer stem cells. Thus, miRNAs have now become important therapeutic targets. This can be achieved by replacing miRNA expression where it has been lost or decreased, or conversely by inhibiting miRNA expression where it has been amplified or overexpressed in cancers. Ultimately, miRNAs should provide both important prognostic biomarkers as well as new targetable molecules for the treatment of breast cancer.
Export Options
About this article
Cite this article as:
B. Greene Stephanie, I. Herschkowitz Jason and M. Rosen Jeffrey, Small Players With Big Roles: MicroRNAs as Targets to Inhibit Breast Cancer Progression, Current Drug Targets 2010; 11(9) . https://dx.doi.org/10.2174/138945010792006762
| DOI https://dx.doi.org/10.2174/138945010792006762 |
Print ISSN 1389-4501 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Allegations from Whistleblowers
- Publishing Ethics
- Increase Visibility Of Your Article
- Self Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design Role of Dietary Xenobiotics-Gene Interactions in Carcinogenesis: Protective Effects of Nutritional Factors
Current Nutrition & Food Science Meet Our Associate Editor
Current Molecular Medicine <i>Ralstonia Mannitolilytica</i>, an Unusual Pathogen in the Neonatal Intensive Care Unit: A Case of Neonatal Sepsis and Literature Review
Infectious Disorders - Drug Targets Synthesis, Biological Evaluation and Docking Studies of 1,3,4-Oxadiazole Fused Benzothiazole Derivatives for Anticancer Drugs
Letters in Drug Design & Discovery Docetaxel/2-Hydroxypropyl β -Cyclodextrin Inclusion Complex Increases Docetaxel Solubility and Release from a Nanochannel Drug Delivery System
Current Drug Targets Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry High Expression of SIRT1 Associates with the Doxorubicin Resistance of Breast Cancer through the Activation of Akt
Anti-Cancer Agents in Medicinal Chemistry Synthesis and <i>in Vitro</i> Cytotoxicity Evaluation of Phenanthrene Linked 2,4- Thiazolidinediones as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot topic: Microbiota, Innate Immune and Anti-Inflammation (Guest Editor: Jun Sun)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Effects of Probiotics and Prebiotics on Gastrointestinal and Behavioural Symptoms in Autism Spectrum Disorder
Current Reviews in Clinical and Experimental Pharmacology Targeting p73 - a Potential Approach in Cancer Treatment
Current Pharmaceutical Design Cytochrome P450 2C8 and Drug Metabolism
Current Topics in Medicinal Chemistry Anti-Epidermal Growth Factor Receptor Strategies to Enhance Radiation Action
Current Medicinal Chemistry - Anti-Cancer Agents Modeling Expression Plasticity of Genes that Differentiate Drug-sensitive from Drug-resistant Cells to Chemotherapeutic Treatment
Current Genomics Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
Current Drug Targets A Single Center Phase II Study of Continuous Infusion of Low-dose 5- fluorouracil for Heavily Pretreated Patients With Metastatic Colorectal Cancer
Clinical Cancer Drugs (Discontinued) Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) Celecoxib Inhibits Helicobacter pylori-induced Invasion of Gastric Cancer Cells Through an Adenine Nucleotide Translocator-Dependent Mechanism
Anti-Cancer Agents in Medicinal Chemistry

